All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Antibiotic resistance is an inevitable outcome whenever antibiotics are used. There are many reasons for this: 1) As humans (also as eukaryotes), we are vastly outnumbered by bacteria in nearly all measures, including total population size, biomass, genetic diversity, emigration, and immigration \[[@pone.0122283.ref001]\]; 2) bacteria can use horizontal gene transfer to share resistance genes across distantly related species of bacteria, including non-pathogens \[[@pone.0122283.ref002]\]; 3) compared to humans, bacteria have relatively few vulnerable target sites \[[@pone.0122283.ref003]\]; 4) microbes are the sources of nearly all antibiotics that are used by humans \[[@pone.0122283.ref004]\]. Given the overwhelming numbers of bacteria, the limited number of target sites, the numerous ways that they can infect humans, and that they have been exposed to naturally occurring antibiotics for billions of years, resistance to antibiotics used by human populations is unavoidable.

Once resistance is present in a bacterial population, it is exceedingly difficult to remove for several reasons. If any amount of antibiotic is present in the environment, antibiotic resistance genes will confer a large fitness advantage \[[@pone.0122283.ref005]\], and even when antibiotics are not present in an environment, the fitness costs for carrying and expressing resistance genes are small to non-existent \[[@pone.0122283.ref006]\]. In addition to it being difficult to remove antibiotics from the environment \[[@pone.0122283.ref007]\], even if humans were to completely abandon the use of antibiotics, resistance would persist for years \[[@pone.0122283.ref008]\].

Efforts to remove resistance genes from clinical environments by either discontinuing or reducing the use of specific antibiotics for some period of time, either through general reduction of antibiotic consumption or periodic rotations of antibiotics (cycling) have not worked in any reliable or reproducible manner \[[@pone.0122283.ref009]\]; indeed it would have been surprising if they had worked \[[@pone.0122283.ref010]\],\[[@pone.0122283.ref011]\].

Since antibiotic resistance *is* unavoidable, it only makes sense to accept its inevitability and develop methods for mitigating the consequences. One reasonable approach is to rotate the use of antibiotics. This has been implemented in many ways and there are recent studies to model the optimal duration, mixing versus cycling, and how relaxed antibiotic cycles may be and still function as planned \[[@pone.0122283.ref012], [@pone.0122283.ref013]\]. However, none of those models have focused on developing a method for designing an optimal succession of antibiotics.

In a previous publication \[[@pone.0122283.ref014]\], we proposed that susceptibility to antibiotics could be restored by rotating consumption of multiple antibiotics that are a) structurally similar, b) inhibit/kill bacteria through the same target site, and c) result in pleiotropic fitness costs that reduce the overall resistance of bacteria to each other. We presented a proof-of-principle example \[[@pone.0122283.ref014]\] of how this might work with a series of β-lactam antibiotics in which some of them would select for new amino acid substitutions in the TEM β-lactamase and others that would select reversions in TEM ultimately leading back to the wild type (un-mutated) state. We have focused particularly on β-lactamases because there is often no fitness cost associated with their expression, and they are particularly difficult to remove from clinical microbial populations.

Our current work seeks to identify β-lactam treatment plans that have the highest probability of returning a population expressing a small number of variant TEM genotypes to the wild type state. The wild type TEM-1, and a handful of its descendants, confers resistance to penicillins alone. However, most of the descendants confer resistance to either cephalosporins or penicillins combined with β-lactamase inhibitors (inhibitor resistance), and a few confer resistance to both. Of the 194 clinically identified TEM genotypes that encode unique amino acid sequences \[[@pone.0122283.ref015]\], 174 (89.7%) differ from the wild type TEM-1 by at most four amino acid substitutions (see [Table 1](#pone.0122283.t001){ref-type="table"}). Our choice of a system that includes four amino acid substitutions is based upon an apparent threshold for amino acid substitutions among functional TEM genotypes. The rarity of the co-existence of cephalosporin resistance and inhibitor resistance and the fact that no single substitution confers both phenotypes suggested that sign epistasis (i.e. reversals of substitutions from beneficial to detrimental) exists as the substitutions that contribute to this dual phenotype are combined. We have assumed that substitutions arise according to the strong selection weak mutation model (SSWM) \[[@pone.0122283.ref016]\] in which single substitutions reach fixation before the next substitution occurs. Recent work \[[@pone.0122283.ref017]\] in addition to past phylogenetic analysis \[[@pone.0122283.ref018]\] and competition experiments \[[@pone.0122283.ref019]\] suggest that this is a valid model for TEM evolution.

10.1371/journal.pone.0122283.t001

###### Distribution of substitutions among TEM enzymes.

![](pone.0122283.t001){#pone.0122283.t001g}

  Number of amino acid substitutions   Number of identified TEM genotypes
  ------------------------------------ ------------------------------------
  1                                    53
  2                                    53
  3                                    37
  4                                    31
  5                                    10
  6                                    2
  7                                    2
  8                                    0
  9                                    0
  10                                   1
  11                                   1

The ability to apply selective pressures that favor reversions of substitutions within an evolved TEM genotype would increase the number of antibiotics that could be used. To embark upon our effort of determining the best way to do this, we decided to create a model system based upon the TEM-50 genotype, which differs from TEM-1 by four amino acid substitutions. All four substitutions by themselves confer clearly defined resistance advantages in the presence of certain antibiotics. Additionally, TEM-50 is one of the few genotypes that simultaneously confers resistance to cephalosporins and inhibitor combined therapies.

Results {#sec002}
=======

From experimental data to mathematical models {#sec003}
---------------------------------------------

We created all 16 variant genotypes of the four amino acid substitutions found in TEM-50 using site directed mutagenesis ([Table 2](#pone.0122283.t002){ref-type="table"}) and measured the growth rates of 12 replicates of *E*.*coli* DH5α-E expressing each genotype in the presence of one of fifteen β-lactam antibiotics ([Table 3](#pone.0122283.t003){ref-type="table"}). Each genotype was grown in each antibiotic in 12 replicates. We computed the mean growth rate of those replicates ([Table 4](#pone.0122283.t004){ref-type="table"}) and the variance of each sample, as well as the significance between adjacent genotypes that differed by one amino acid substitution. This was done using one-way ANOVA analysis.

10.1371/journal.pone.0122283.t002

###### Variant Genotypes Created, Binary Codes, Substitutions and (Names of Genotypes Identified in Clinical Isolates).
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  Number of Substitutions   Binary Genotype Code   Genotypes with substitutions found in TEM-50
  ------------------------- ---------------------- ----------------------------------------------
  0                         0000                   No substitutions, (TEM-1)
  1                         1000                   M69L, (TEM-33)
  1                         0100                   E104K, (TEM-17)
  1                         0010                   G238S, (TEM-19)
  1                         0001                   N276D, (TEM-84)
  2                         1100                   M69L, E104K, (Not identified)
  2                         1010                   M69L, G238S, (Not identified)
  2                         1001                   M69L, N276D, (TEM-35)
  2                         0110                   E104K, G238S, (TEM-15)
  2                         0101                   E104K, N276D, (Not identified)
  2                         0011                   G238S, N276D, (Not identified)
  3                         1110                   M69L, E104K, G238S, (Not identified)
  3                         1101                   M69L, E104K, N276D, (Not Identified)
  3                         1011                   M69L, G238S, N276D, (Not identified)
  3                         0111                   E104K, G238S, N276D, (Not identified)
  4                         1111                   M69L, E104K, G238S, N276D, (TEM-50)

10.1371/journal.pone.0122283.t003

###### β-lactam Antibiotics used for this study.

![](pone.0122283.t003){#pone.0122283.t003g}

  β-lactam Antibiotic                   FDA approval   Antibiotic Group
  ------------------------------------- -------------- -----------------------------------------------
  Ampicillin (AMP)                      1963           Aminopenicillin
  Amoxicillin (AM)                      1972           Aminopenicillin
  Cefaclor (CEC)                        1979           Cephalosporin
  Cefotaxime (CTX)                      1981           Cephalosporin
  Ceftizoxime (ZOX)                     1983           Cephalosporin
  Cefuroxime (CXM)                      1983           Cephalosporin
  Ceftriaxone (CRO)                     1984           Cephalosporin
  Amoxicillin + Clavulanic acid (AMC)   1984           Penicillin derivative + β-Lactamase inhibitor
  Ceftazidime (CAZ)                     1985           Cephalosporin
  Cefotetan (CTT)                       1985           Cephalosporin
  Ampicillin + Sulbactam (SAM)          1986           Penicillin derivative + β-Lactamase inhibitor
  Cefprozil (CPR)                       1991           Cephalosporin
  Cefpodoxime (CPD)                     1992           Cephalosporin
  Pipercillin + Tazobactam (TZP)        1993           Penicillin derivative + β-Lactamase inhibitor
  Cefepime (FEP)                        1996           Cephalosporin

10.1371/journal.pone.0122283.t004

###### Average Growth Rates (x 10^--3^): the rows are the fitness landscapes.
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            0000       1000       0100       0010       0001       1100       1010       1001
  --------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  **AMP**   1.851      1.570      2.024      1.948      2.082      2.186      0.051      2.165
  **AM**    1.778      1.720      1.448      2.042      1.782      1.557      1.799      2.008
  **CEC**   2.258      0.234      2.396      2.151      1.996      2.150      2.242      0.172
  **CTX**   0.160      0.185      1.653      1.936      0.085      0.225      1.969      0.140
  **ZOX**   0.993      1.106      1.698      2.069      0.805      1.116      1.894      1.171
  **CXM**   1.748      0.423      2.940      2.070      1.700      2.024      1.911      1.578
  **CRO**   1.092      0.830      2.880      2.554      0.287      1.407      3.173      0.540
  **AMC**   1.435      1.417      1.672      1.061      1.573      1.377      1.538      1.351
  **CAZ**   2.134      0.288      2.042      2.618      2.656      2.630      1.604      0.576
  **CTT**   2.125      3.238      3.291      2.804      1.922      0.546      2.883      2.966
  **SAM**   1.879      2.198      2.456      0.133      2.533      2.504      2.308      2.570
  **CPR**   1.743      1.553      2.018      1.763      1.662      0.223      0.165      0.256
  **CPD**   0.595      0.432      1.761      2.604      0.245      0.638      2.651      0.388
  **TZP**   2.679      2.709      3.038      2.427      2.906      2.453      0.172      2.500
  **FEP**   2.590      2.067      2.440      2.393      2.572      2.735      2.957      2.446
            **0110**   **0101**   **0011**   **1110**   **1101**   **1011**   **0111**   **1111**
  **AMP**   2.033      2.198      2.434      0.088      2.322      0.083      0.034      2.821
  **AM**    1.184      1.544      1.752      1.768      2.247      2.005      0.063      2.047
  **CEC**   2.230      1.846      2.648      2.640      0.095      0.093      0.214      0.516
  **CTX**   2.295      0.138      2.348      0.119      0.092      0.203      2.269      2.412
  **ZOX**   2.138      2.010      2.683      1.103      1.105      0.681      2.688      2.591
  **CXM**   2.918      2.173      1.938      1.591      1.678      2.754      3.272      2.923
  **CRO**   2.732      0.656      3.042      2.740      0.751      1.153      0.436      3.227
  **AMC**   0.073      1.625      1.457      1.307      1.914      1.590      0.068      1.728
  **CAZ**   2.924      2.756      2.688      2.893      2.677      1.378      0.251      2.563
  **CTT**   3.082      2.888      0.588      3.193      3.181      0.890      3.508      2.543
  **SAM**   0.083      2.437      0.094      2.528      3.002      2.886      0.094      3.453
  **CPR**   2.042      2.050      1.785      1.811      0.239      0.221      0.218      0.288
  **CPD**   2.910      1.471      3.043      0.963      0.986      1.103      3.096      3.268
  **TZP**   2.528      3.309      0.141      0.609      2.739      0.093      0.143      0.171
  **FEP**   2.652      2.808      2.832      2.796      2.863      2.633      0.611      3.203

The results are summarized in Figs [1](#pone.0122283.g001){ref-type="fig"}--[15](#pone.0122283.g015){ref-type="fig"}, where the arrows in the fitness graphs connect pairs of adjacent genotypes. For each comparison of adjacent genotypes, we indicate the one whose expression resulted in the faster growth by directing the arrowhead towards that genotype, and implying that evolution would proceed in that direction if the two genotypes occurred simultaneously in a population \[[@pone.0122283.ref020], [@pone.0122283.ref021]\]. In other words, the node indicated by the arrowhead would increase in frequency and reach fixation in the population, while the other would be lost. Red arrows indicate significance, and black arrows indicate differences that were not statistically significant by ANOVA, but that may still exist if a more sensitive assay was used.

![AMP: Ampicillin 256 μg/ml.](pone.0122283.g001){#pone.0122283.g001}

![AM: Amoxicillin 512 μg/ml.](pone.0122283.g002){#pone.0122283.g002}

![CEC: Cefaclor 1 μg/ml.](pone.0122283.g003){#pone.0122283.g003}

![CTX: Cefotaxime 0.05 μg/ml.](pone.0122283.g004){#pone.0122283.g004}

![ZOX: Ceftizoxime 0.03 μg/ml.](pone.0122283.g005){#pone.0122283.g005}

![CXM: Cefuroxime 1.5 μg/ml.](pone.0122283.g006){#pone.0122283.g006}

![CRO: Ceftriaxone 0.045 μg/ml.](pone.0122283.g007){#pone.0122283.g007}

![AMC: Amoxicillin/Clavulanate 512 μg/ml and 8μg/ml.](pone.0122283.g008){#pone.0122283.g008}

![CAZ: Cefazidime 0.1 μg/ml.](pone.0122283.g009){#pone.0122283.g009}

![CTT: Cefotetan 0.312 μg/ml.](pone.0122283.g010){#pone.0122283.g010}

![SAM: Ampicillin/Sulbactam 8 μg/ml and 8μg/ml.](pone.0122283.g011){#pone.0122283.g011}

![CPR: Cefprozil 100 μg/ml.](pone.0122283.g012){#pone.0122283.g012}

![CPD: Cefpodoxime 2 μg/ml.](pone.0122283.g013){#pone.0122283.g013}

![TZP: Pipercillin / Tazobactam 8.12μg/ml and 8 μg.ml.](pone.0122283.g014){#pone.0122283.g014}

![FEP: Cefepime 0.0156μg/ml.](pone.0122283.g015){#pone.0122283.g015}

**Figs [1](#pone.0122283.g001){ref-type="fig"}--[15](#pone.0122283.g015){ref-type="fig"}.** These figures present fitness graphs, which are a visual summary of the adaptive landscape 2x2x2x2 tensors in which each resistance phenotype conferred by each TEM genotype is enumerated. Arrows pointing upward represent selection for the addition of a substitution. Arrows pointing downward represent selection for reversions. Red arrows indicate significance between adjacent growth rates as determined by one way ANOVA. Genotypes that confer the most resistance to each antibiotic are shown in red.

We rank ordered the genotypes ([Table 5](#pone.0122283.t005){ref-type="table"}) in each landscape diagram with a score from 1 to 16, with the genotype promoting the fastest growth receiving a score of "1" and the genotype with the slowest growth a score of "16". This analysis shows that all genotypes have a score of 5 or better and a score of 13 or worse, in at least one landscape, indicating that there is abundant pleiotropy as antibiotic selective pressures change. That pleiotropy provides a basis for effectively alternating antibiotic to restore the wild type.

10.1371/journal.pone.0122283.t005

###### Rank Order of Genotypes in Each β-Lactam Antibiotic (Derived From [Table 4](#pone.0122283.t004){ref-type="table"}).
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  Antibiotic     0000   1000   0100   0010   0001   1100   1010   1001   0110   0101   0011   1110   1101   1011   0111   1111
  -------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  AMP            11     12     9      10     7      5      15     6      8      4      2      13     3      14     16     1
  AM             8      11     14     3      7      12     6      4      15     13     10     9      1      5      16     2
  CEC            4      12     3      7      9      8      5      14     6      10     1      2      15     16     13     11
  CTX            11     10     7      6      16     8      5      12     3      13     2      14     15     9      4      1
  ZOX            14     11     8      5      15     10     7      9      4      6      2      3      12     16     1      3
  CXM            11     16     2      7      12     8      10     15     4      6      9      14     13     5      1      3
  CRO            10     11     4      7      16     8      2      14     6      13     3      5      12     9      15     1
  AMC            9      10     3      14     6      11     7      12     15     4      8      13     1      5      16     2
  CAZ            10     15     11     8      6      7      12     14     1      3      4      2      5      13     16     9
  CTT            12     3      2      10     13     16     9      7      6      8      15     4      5      14     1      11
  SAM            12     11     8      13     5      7      10     4      16     9      14     6      2      3      15     1
  CPR            7      9      3      6      8      13     16     11     2      1      5      4      12     14     15     10
  CPD            13     14     7      6      16     12     5      15     4      8      3      11     10     9      2      1
  TZP            6      5      2      10     3      9      12     8      7      1      15     11     4      16     14     13
  FEP            10     15     13     14     11     7      2      12     8      5      4      6      3      9      16     1
  Best value     4      3      2      3      3      5      2      4      1      1      1      2      1      3      1      1
  Worst value    14     16     14     14     16     16     15     15     16     13     15     14     15     16     16     13
  Median value   10     11     7      7      9      8      7      12     6      6      4      6      5      9      15     2

Based on the strong patterns of pleiotropy we observed, we reasoned that the choice and the succession of antibiotics were at least as important as other cycling considerations. We formalized our approach to identifying optimal antibiotic treatment paths as follows.

We considered the 15 antibiotics previously mentioned in [Table 3](#pone.0122283.t003){ref-type="table"}: AMP, AM, CEC, CTX, ZOX, CXM, CRO, AMC, CAZ, CTT, SAM, CPR, CPD, TZP, and FEP and their interactions with a bi-allelic 4-locus TEM system {0,1}^4^ where four functionally important amino acid residues involved in the evolution of TEM-50 are considered. The number \"1\" denotes an amino acid substitution, whereas \"0\" denotes no substitution at the site. We experimentally determined growth rates for all genotypes in our TEM system at a selected concentration of each antibiotic. Those growth rates depend upon the states of the four amino acid residues. The growth rates for all genotypes in one antibiotic can be represented by a real 2×2×2×2 tensor *f* = (*f* ~*ijkl*~), where *f*(*a* ~*r*~) is the fitness landscape for the antibiotic *r*. We can identify *f*(*a* ~*r*~) with a vector whose coordinates are indexed by {0,1}^4^. The resulting 15 vectors, one for each antibiotic, are the rows in [Table 4](#pone.0122283.t004){ref-type="table"}.

Our substitution model *M*(*f*) is a function $\left. M:{\mathbb{R}}^{16}\rightarrow{\mathbb{R}}^{16 \times 16} \right.$ that assigns a transition matrix to each fitness landscape. The rows and columns of *M*(*f*) are labeled by the genotypes {0,1}^4^ according to the degree lexicographic order. The entries in *M*(*f*(*a* ~*r*~))~*u*,*v*~ represent the probability that that genotype *u* is replaced by genotype *v* under the presence of antibiotic *a* ~*r*~. For that reason, the rows of our transition matrices have nonnegative entries and their rows sum to 1.

We require that our transition matrices respect the adjacency structure of the 4-cube, that is, *M*(*f*)~*u*,*v*~ = 0 unless *u* and *v* are vectors in {0,1}^4^ that differ in at most one coordinate. In other words, we reasoned that resistant strains are most likely to be in competition with those that express resistance genotypes that are immediately adjacent (vary by a single amino acid substitution).

The combined effect of a sequence *a* ~1~,...,*a* ~*k*~ of *k* antibiotics is described by a new transition matrix $$M\left( f_{a_{1}} \right) \cdot M\left( f_{a_{2}} \right) \cdot ... \cdot M\left( f_{a_{k}} \right)$$ obtained as the product of the transition matrices for each drug.

For any genotype u other than 0000, our goal is to find a sequence of antibiotics which maximizes the probability of returning to the wild type. In other words, if we restrict to sequences of length k our goal is to find a sequence of antibiotics *a* ~1~,...,*a* ~*k*~ which maximizes the matrix entry *M*(*f*(*a* ~1~))·*M*(*f*(*a* ~2~))·...·*M*(*f*(*a* ~*k*~))~*u*,0000~. For each *u* this requires searching over all 15^*k*^ antibiotic sequences of length *k*.

Finding optimal sequences of antibiotics {#sec004}
----------------------------------------

We used two substitution models to determine the optimal (highest probability) sequences of β-lactams for returning TEM genotypes back to their wild type state. Briefly, the Correlated Probability Model (CPM) allows probabilities to be based upon the actual growth rates. It is given by applying Eq ([3](#pone.0122283.e006){ref-type="disp-formula"}) to the growth rates in [Table 4](#pone.0122283.t004){ref-type="table"}. The Equal Probability Model (EPM) assumes that beneficial substitutions are equally likely and that only the direction of the arrows in Figs [1](#pone.0122283.g001){ref-type="fig"}--[15](#pone.0122283.g015){ref-type="fig"} is important. This means that the matrix entry *M*(*f*)~*u*,*v*~ is 1/*N* if genotype *u* has *N* outgoing arrows and there is an arrow from *u* to *v*.

A visual summary of the highest probabilities according to the CPM is provided in [Fig 16](#pone.0122283.g016){ref-type="fig"}. The CPM provides good estimates if fitness differences between genotypes are small \[[@pone.0122283.ref014], [@pone.0122283.ref022]--[@pone.0122283.ref024]\]. The EPM has been used in settings where only rank order (as in [Table 5](#pone.0122283.t005){ref-type="table"}) is available \[[@pone.0122283.ref025]\].

![Summary of CPM Substitutions with the Highest Probabilities.\
Each arrow is labeled by the drug or drugs corresponding to the maximal transition probability, taken over all 15 drugs. Each arrow is also labeled by the maximal probability. The top panel shows which antibiotics selected the addition of substitutions and the bottom panel shows which antibiotics selected reversions. Unlabled arrows are those with low probabilities across all antibiotics.](pone.0122283.g016){#pone.0122283.g016}

From the graph, it is possible to find candidate treatment plans. For example, when starting at genotype 1010 the graph shows that the probability for ending at 0000 is 0.71for the sequence ZOX-TZP (0.71 is the product of the arrow labels). Similarly, when starting at 1111 the probability for ending at 0000 is 0.62 for the sequence CEC-CAZ-TZP-AM. When starting at 0001 the graphs shows that a single drug gives probability at most 0.29, whereas the probability for ending at 0000 for the sequence AMC-CRO-AM (one arrow up, two arrows down) is at least 0.96·0.62 = 0.6.

This graph can also be used to generate treatment paths that start and end at the same genotype, making possible the development of a fixed treatment plan. For example, from a starting point 0000, the probability for ending at 0000 is 0.62 for the sequence: CEC-CTX-ZOX-CPD-CPR-CAZ-TZP-AM

For all sequences of antibiotics of a fixed length (two, three, four, five, and six), we examined the probability that a given genotype is returned to the wild type state. It is worth noting that within these paths, a single genotype can be repeated consecutively with different antibiotics, thus making it possible to have an odd number of steps in the treatment paths when an even number of subtitutions are introduced. For every starting genotype, we found we were able to return to the wild type genotype with a probability between 0.6 and 1.0 when using the CPM model and a probability of 0.375 and 1.0 when using the EPM model. These results are summarized in Tables [6](#pone.0122283.t006){ref-type="table"}--[9](#pone.0122283.t009){ref-type="table"} and [Fig 17](#pone.0122283.g017){ref-type="fig"}. These results show the number of paths and their probabilities (Tables [6](#pone.0122283.t006){ref-type="table"} and [7](#pone.0122283.t007){ref-type="table"}) and the substitutions selected through the optimal treatment plans (Tables [8](#pone.0122283.t008){ref-type="table"}--[11](#pone.0122283.t011){ref-type="table"}) for returning to the wild type state from various starting points.

![Summary of Optimal 6 Step CPM and EPM Treatment Paths beginning at genotype 1111 and ending at genotype 0000.\
An arrow indicates that the substitution is included in a path that starts at 1111 and ends at 0000, where the pathway has non-zero probability. Black arrows show substitutions present in six step paths computed using both the CPM and the EPM. Red arrows signify substitutions found only in optimum paths computed using the CPM whereas blue signify substitutions only found using the EPM.](pone.0122283.g017){#pone.0122283.g017}

10.1371/journal.pone.0122283.t006

###### Maximum Probability and Number of Paths Using CPM.

![](pone.0122283.t006){#pone.0122283.t006g}

  Starting Genotype   1 Step   No. of paths   2 Step   No. of paths   3 Step   No. of paths   4 Step   No. of paths   5 Step   No. of paths   6 Step   No. of paths
  ------------------- -------- -------------- -------- -------------- -------- -------------- -------- -------------- -------- -------------- -------- --------------
  1000                1.0      1              1.0      3              1.0      7              1.0      15             1.0      31             1.0      63
  0100                0.617    1              0.617    6              0.617    36             0.617    219            0.617    1360           0.617    8568
  0010                0.715    1              0.715    2              0.715    3              0.715    4              0.715    5              0.715    6
  0001                0.287    1              0.287    1              0.592    2              0.592    8              0.726    2              0.726    4
  1100                \-                      0.617    3              0.617    18             0.617    108            0.617    657            0.617    4110
  1010                \-                      0.715    1              0.715    6              0.715    27             0.715    112            0.715    453
  1001                \-                      0.559    1              0.559    4              0.726    1              0.726    2              0.729    1
  0110                \-                      0.617    1              0.617    10             0.617    78             0.617    555            0.617    3805
  0101                \-                      0.592    1              0.592    9              0.612    1              0.612    9              0.617    34
  0011                \-                      0.361    1              0.361    9              0.586    2              0.600    2              0.617    8
  1110                \-                      \-                      0.617    2              0.617    24             0.617    215            0.617    1720
  1101                \-                      \-                      0.592    2              0.592    24             0.617    12             0.617    252
  1011                \-                      \-                      0.532    1              0.532    1              0.684    1              0.690    1
  0111                \-                      \-                      0.586    1              0.600    1              0.617    4              0.617    84
  1111                \-                      \-                      \-       \-             0.617    4              0.617    72             0.617    906

10.1371/journal.pone.0122283.t007

###### Maximum Probability and Number of Paths Using EPM.

![](pone.0122283.t007){#pone.0122283.t007g}

  Starting Genotype   1 Step   No. of paths   2 Step   No. of paths   3 Step   No. of paths   4 Step   No. of paths   5 Step   No. of paths   6 Step   No. of paths
  ------------------- -------- -------------- -------- -------------- -------- -------------- -------- -------------- -------- -------------- -------- --------------
  1000                1.0      1              1.0      3              1.0      7              1.0      15             1.0      31             1.0      63
  0100                0.33     1              0.33     6              0.33     39             0.38     1              0.46     1              0.46     9
  0010                0.50     1              0.50     4              0.50     6              0.50     8              0.50     10             0.50     12
  0001                0.50     1              0.50     1              0.66     4              0.66     8              0.66     14             0.66     24
  1100                \-                      0.33     27             0.39     1              0.39     1              0.39     4              0.46     5
  1010                \-                      0.50     3              0.50     19             0.58     1              0.58     8              0.59     1
  1001                \-                      0.66     2              0.66     4              0.66     7              0.66     12             0.69     1
  0110                \-                      0.33     1              0.33     10             0.33     81             0.38     1              0.46     1
  0101                \-                      0.29     1              0.38     1              0.46     1              0.46     4              046      1
  0011                \-                      0.25     4              0.25     32             0.50     2              0.50     18             0.50     133
  1110                \-                      \-                      0.33     2              0.33     24             0.33     221            0.38     6
  1101                \-                      \-                      0.29     2              0.38     2              0.46     2              0.46     14
  1011                \-                      \-                      0.33     3              0.33     8              0.39     1              0.52     1
  0111                \-                      \-                      0.15     1              0.20     8              0.33     4              0.38     6
  1111                \-                      \-                      \-       \-             0.33     4              0.38     4              0.46     4

10.1371/journal.pone.0122283.t008

###### CPM Additions of Substitutions And Associated β-lactam Antibiotics From Optimal Six Step Treatment Plans (\*Maximum Probability for Path).

![](pone.0122283.t008){#pone.0122283.t008g}

  Substitutions   Drugs associated with substitutions in optimal paths (probability)
  --------------- --------------------------------------------------------------------
  0000--1000      CTT(0.38\*)
  0000--0100      
  0000--0010      
  0000--0001      
  1000--1100      
  1000--1010      
  1000--1001      
  0100--1100      SAM(1.0\*)
  0100--0110      CTX(1.0\*), CPD(1.0\*)
  0100--0101      
  0010--1010      CTT(0.22)
  0010--0110      
  0010--0011      
  0001--1001      AM(1.0\*), CTT(0.47), SAM(1.0\*)
  0001--0101      
  0001--0011      
  1100--1110      CAZ(0.85\*), SAM(0.046), FEP(0.32)
  1100--1101      AMP(1.0\*),CAZ(0.15), SAM(0.95), FEP(0.68)
  1010--1110      CEC(1.0\*), CTT(0.47)
  1010--1011      
  1001--1101      
  1001--1011      CTX(0.50\*)
  0110--1110      FEP(1.0\*)
  0110--0111      ZOX(1.0\*), CXM(0.94), CPD(1.0\*)
  0101--1101      AMP(1.0\*), FEP(1.0\*)
  0101--0111      CTX(0.58), ZOX(1.0\*), CXM(0.59), CPD(0.85)
  0011--1011      CTT(0.04)
  0011--0111      ZOX(1.0\*), CPD(1.0\*)
  1110--1111      AM(0.90), CRO(0.53), SAM(1.0\*), CPD(0.39), FEP(0.72)
  1101--1111      AMP(1.0\*), SAM(1.0\*), FEP(1.0\*)
  1011--1111      TZP(0.03)
  0111--1111      CPD(1.0\*)

10.1371/journal.pone.0122283.t009

###### CPM Reversions of Substitutions And Associated β-lactam Antibiotics From Optimal Six Step Treatment Plans (\*Maximum Probability for Path).

![](pone.0122283.t009){#pone.0122283.t009g}

  Reversions   Drugs associated with substitutions in optimal paths (probability)
  ------------ --------------------------------------------------------------------
  1111--1110   CEC(1.0\*), CAZ(0.74), CTT(0.29), CPR(1.0\*), TZP(0.15)
  1111--1101   AM(1.0\*), AMC(1.0\*), CAZ(0.26), TZP(0.85)
  1111--1011   
  1111--0111   ZOX(1.0\*), CXM(1.0\*)
  1110--1100   TZP(0.49\*)
  1110--1010   AM(0.10), CRO(0.47\*), CPD(0.28), FEP(0.28)
  1110--0110   CAZ(1.0\*), CPR(1.0\*), CPD(0.33), TZP(0.51)
  1101--1100   
  1101--1001   
  1101--0101   
  1011--1010   TZP(0.30)
  1011--1001   TZP(0.92\*)
  1011--0011   TZP(0.18)
  0111--0110   
  0111--0101   
  0111--0011   
  1100--1000   CTT(0.25)
  1100--0100   CTX(1.0\*), ZOX(1.0\*), CXM(1.0\*)
  1010--1000   CTT(0.53\*), TZP(0.49)
  1010--0010   ZOX(1.0\*), TZP(0.43)
  1001--1000   CTX(0.42), CTT(0.56)
  1001--0001   
  0110--0100   CXM(0.58), TZP(1.0\*)
  0110--0010   
  0101--0100   CTX(0.42), CXM(0.41), CPD(0.15)
  0101--0001   
  0011--0010   CTT(0.33), TZP(0.45)
  0011--0001   CTT(0.20), TZP(0.55)
  1000--0000   CPR(1.0\*)
  0100--0000   AM(0.62\*)
  0010--0000   TZP(0.71\*)
  0001--0000   CTT(0.092), CPR(0.14)

10.1371/journal.pone.0122283.t010

###### EPM Additions of Substitutions and Associated β-lactam Antibiotics From Optimal Six Step Treatment Plans (\*Maximum Probability for Path).

![](pone.0122283.t010){#pone.0122283.t010g}

  Mutations    β-lactams associated with substitutions in optimal paths (probability)
  ------------ ------------------------------------------------------------------------
  0000--1000   
  0000--0100   
  0000--0010   
  0000--0001   
  1000--1100   
  1000--1010   
  1000--1001   
  0100--1100   SAM(1.0\*)
  0100--0110   
  0100--0101   TZP(1.0\*)
  0010--1010   
  0010--0110   
  0010--0011   
  0001--1001   AM(1.0\*), SAM(1.0\*)
  0001--0101   TZP(1.0\*)
  0001--0011   
  1100--1110   CTT(1/4)
  1100--1101   AMP(1.0\*), CPR(1/4)
  1010--1110   CTT(1/2)
  1010--1011   
  1001--1101   
  1001--1011   CTX(1/2\*)
  0110--1110   CTT(1/3)
  0110--0111   
  0101--1101   AM(1/2), AMC(1/2)
  0101--0111   
  0011--1011   AMC(1/2\*)
  0011--0111   
  1110--1111   SAM(1.0\*)
  1101--1111   
  1011--1111   CTT(1/3)
  0111--1111   SAM(1/2), CPD(1.0\*)

10.1371/journal.pone.0122283.t011

###### EPM Reversions of Substitutions and Associated β-lactam Antibiotics From Optimal Six Step Treatment Plans (\*Maximum Probability for Path).

![](pone.0122283.t011){#pone.0122283.t011g}

  Reversions   β-lactams associated with substitutions in optimal paths (probability)
  ------------ ------------------------------------------------------------------------
  1111--1110   CTT(1/3)
  1111--1101   AM(1.0\*), AMC(1.0\*)
  1111--1011   
  1111--0111   
  1110--1100   TZP(1/2\*)
  1110--1010   
  1110--0110   CAZ(1.0\*), CPR(1.0\*), TZP(1/2)
  1101--1100   
  1101--1001   CPR(1/3\*)
  1101--0101   CAZ(1.0\*), TZP(1.0\*)
  1011--1010   CTT(1/3\*)
  1011--1001   AM(1/2\*), CTT(1/3)
  1011--0011   
  0111--0110   
  0111--0101   SAM(1/2\*)
  0111--0011   
  1100--1000   CTT(1/4), CPR(1/4), TZP(1/3\*)
  1100--0100   CTX(1.0\*), ZOX(1.0\*), CXM(1.0\*)
  1010--1000   CTT(1/2\*), TZP(1/3)
  1010--0010   
  1001--1000   CEC(1/2\*), CTX(1/2\*), CTT(1/2\*), CPR(1/2\*), TZP(1/3)
  1001--0001   CEC(1/2\*), CPR(1/2\*)
  0110--0100   TZP(1.0\*)
  0110--0010   
  0101--0100   CEC(1/2\*), AMC(1/2\*)
  0101--0001   AM(1/2\*), CEC(1/2\*)
  0011--0010   
  0011--0001   AMC(1/2\*)
  1000--0000   CPR(1.0\*)
  0100--0000   FEP(1/4)
  0010--0000   SAM(1/2\*), TZP(1/2\*)
  0001--0000   CEC(1/2\*), CPR(1/3), FEP(1/3)

Once returned to the wild type state, we identified cycles that would allow for alternation of antibiotics, and allow for some variation through amino acid substitution, but then rapidly return bacteria to the wild type state ([Table 12](#pone.0122283.t012){ref-type="table"} and [Fig 18](#pone.0122283.g018){ref-type="fig"}). Such cycles were possible for path length of two, four, and six and the probabilities of those paths were respectively 0.704, 0.617, 0.617. We found that in the most probable cases, the genotype varied by only one amino acid substitution before reverting back to the wild type state. However, when treatment plans with lower probabilities are considered, we find that more amino acid substitutions in the genotype are allowed.

![Summary of Optimal CPM 2, 4, and 6 Step Antibiotic Cycles.\
In this figure, cycles are distinguished from paths in that TEM-1 (0000) is the first and last genotype visited, thus creating circular paths. An arrow indicates a substitution included in a mutational pathway which starts and ends at 0000, where the mutational pathway has a non-zero probability for the optimal treatment cycle. The substitutions that are included in optimal two steps cycles are shown in red. Substitutions that are included in optimal four and six step cycles are shown in blue. Four and six step cycles differ only in the number of substitutions and reversions that occur within each cycle. Their probabilities are identical.](pone.0122283.g018){#pone.0122283.g018}

10.1371/journal.pone.0122283.t012

###### Cyclical Treatment Paths showing Substitutions and Associated β-lactam Antibiotics.

![](pone.0122283.t012){#pone.0122283.t012g}

  Path length and probability (prob)   0000-0010/ 0010--0000   0000-0100/ 0100--0000   0100-0110/ 0110--0100                              0100-1100/ 1100--0100
  ------------------------------------ ----------------------- ----------------------- -------------------------------------------------- -----------------------
  **2-step (0.70)**                                                                                                                       
      Cycle 1                          AM/TZP                                                                                             
  **4-step (0.62)**                                                                                                                       
      Cycle 2                                                  CEC/AM                  CTX/TZP                                            
      Cycle 3                                                  CEC/AM                                                                     SAM/CTX
      Cycle 4                                                  CEC/AM                                                                     SAM/ZOX
      Cycle 5                                                  CEC/AM                                                                     SAM/CXM
      Cycle 6                                                  CEC/AM                  CPD/TZP                                            
  **6-step (0.62)**                                                                                                                       
      Cycle 7                                                  CEC/AM                  CTX/TZP(2x)[\*](#t012fn001){ref-type="table-fn"}   
      Cycle 8                                                  CEC/AM                  CTX/TZP                                            SAM/CTX
      Cycle 9                                                  CEC/AM                  CTX/TZP                                            SAM/ZOX
    Cycle 10                                                   CEC/AM                  CTX/TZP                                            SAM/CXM
    Cycle 11                                                   CEC/AM                  CTX/TZP, CPD/TZP                                   

\*Steps visited twice along the paths

Discussion {#sec005}
==========

In this study, we have developed an experimental approach for measuring pleiotropy and a computational mathematical approach for optimizing antibiotic treatment paths. The experimental approach we developed is rapid and high throughput, consistent with previous work \[[@pone.0122283.ref026]\], and should be applicable to many species of resistant bacteria. The mathematical model we created expresses the problem of antibiotic resistance in general terms, and can therefore be applied to other resistance phenotypes where pleiotropy occurs to identify the antibiotic treatment plans that have the highest probability of reversing the evolution of resistance.

The purpose of this study was to determine whether it is possible to use selective pressures to return TEM-genotypes to the wild type state, as observed in 1963 when TEM-1 was originally isolated. The methods may also be used to select for any particular genotype within our data set. As such, we may select with reasonably high probabilities, resistance genotypes that existed at some prior point in time. To highlight this feature, we have named our software package "Time Machine".

Once given growth rates of adjacent genotypes, Time Machine returned treatment plans that restored the wild type state as observed in 1963 with probabilities greater than 0.6 when using the CPM model and greater than 3/8 (\>0.375) when using EPM. These results suggest that when possible it is desirable to use actual growth rates rather than rough ranking data.

While these treatment methods may have clinical value, we have yet to determine the ideal duration of each therapy. Additionally the antibiotics included in our study may have different applications in the clinic. A further issue is that if new genotypes arise, the treatment plan may fail. The inclusion of more resistance genes in this type of approach may aid in the creation of robust treatment plans that are effective even when unexpected genotypes arise.

The discrete optimization problem motivated by our goal to reverse resistance, or the challenge to build a better time machine, is of independent mathematical interest. Tables [6](#pone.0122283.t006){ref-type="table"} and [7](#pone.0122283.t007){ref-type="table"} suggest that the maximum probabilities in each row stagnate after a limited number of steps. This is not always the case. We have created an example (see supplemental information) of two substitution matrices on a 3-locus system where the maximum probabilities can be increased indefinitely ([S1 Fig](#pone.0122283.s001){ref-type="supplementary-material"}).

These results show that great potential exists for remediation of antibiotic resistance through antibiotic treatment plans when pleiotropic fitness costs are known for an appropriate set of antibiotics. While developed using a model of Gram-negative antibacterial resistance, this approach could also be used for Gram-positive bacteria and HIV treatment plans.

Methods {#sec006}
=======

Experimental methods {#sec007}
--------------------

### Strains and Cultures {#sec008}

We expressed 16 mutant constructs of the bla~TEM~ gene in plasmid pBR322 from strain DH5-αE. The 16 genotypes differ at all combinations of four amino acid residues and have been previously described \[[@pone.0122283.ref014]\]. We grew them overnight (16 hours) in standing cultures and diluted them to a concentration of 1.9X10^5^ as described elsewhere \[[@pone.0122283.ref014]\].

We transferred 80 μl of each culture to a 384-well plate with one genotype present in each of the 16 rows. The first 12 wells of each row were antibiotic free (controls) and the last 12 wells contained a single antibiotic at an inhibitory, sublethal concentration. We tested many concentrations and used those that maximized our ability to make comparisons between alleles.

After plating, a membrane is placed over the plate and simultaneously incubated/measured in the Eon Microplate Spectrophotometer at a temperature of 25.1°C for 22 hours. This relatively cool (\<37°) temperature is used because degradation of the antibiotics is much slower, while the growth rate of the bacteria is still sufficient to capture the complete exponential period of growth over the duration of the experiment. Overall, we have found that a temperature \~25°C yields more reliable and consistent measurement of growth rates in the presence of antibiotics.

Measurements of cell density (light scattering) at a wavelength of 600 nanometers were automatically collected every 20 minutes after brief agitation to homogenize and oxygenate the culture.

### Growth Rates {#sec009}

The data obtained from the microplate spectrophotometer is exported to the GrowthRates program to derive the growth rates. In essence, by measuring the optical density at frequent intervals the GrowthRates program can estimate the growth rate,α, through a linear regression algorithm fitting the data from the exponential growth phase. Details can be found in \[[@pone.0122283.ref027]\] in the section entitled "The Growth Curve" located on pages 233--4. There is not a direct or simple correlation between this method and other methods such as minimum inhibitory (MIC) or disk diffusion testing. The output of this program for the data we collected was a list *f*(*a* ~1~),*f*(*a* ~2~),...,*f*(*a* ~*k*~) of 15 tensors, each of format 2×2×2×2. These are the rows in [Table 4](#pone.0122283.t004){ref-type="table"}. So if *u* ∊ {0,1}^4^ is a genotype, then *f*(*a* ~*i*~)~*u*~ is the fitness of genotype *u* in the presence of antibiotic *a* ~*i*~. This fitness is a growth rate, so we are here using the letter *f* for a quantity often denoted by α.

One-Way Analysis of Variance (ANOVA) was then used to compare the means of the growth rates obtained, and to determine if there were significant differences between the growth rates of adjacent genotypes.

*Correlated Probability Model (CPM)*: Once the growth rates have been determined under various experimental conditions, the next step is to use them to compute fixation probabilities.

If the (multiplicative) absolute fitnesses *W* ~*u*~ and *W* ~*v*~ of two neighboring genotypes *u* and *v*, differ by a small quantity then the (additive) relative fitness $\ln\left( \frac{W_{u}}{W_{v}} \right)$ can be approximated by $$\ln\left( \frac{W_{v}}{W_{u}} \right) = T\left( {f_{v} - f_{u}} \right)$$ where *T* is the generation time. Using a Taylor series approximation, $${\ln\left( \frac{W_{v}}{W_{u}} \right) \approx \frac{W_{v}}{W_{u}} - 1}.$$

If *W* ~*v*~ \> *W* ~*u*~, then $$p_{u,v} = \frac{f_{v} - f_{u}}{\sum\left( {f_{uj} - f_{u}} \right)}$$ is the probability for *v* to substitute *u*, where *uj* are the neighbors of *u* with higher fitness than *u* \[[@pone.0122283.ref023]\].

*Equal Probability Model (EPM)*: According to the EPM model, the probabilities are equal for all beneficial substitutions, so that one needs the fitness graphs only for computing the probabilities. The matrix entry *M*(*f*)~*u*,*v*~ is 1/*N* if genotype *u* has *N* outgoing arrows and there is an arrow from *u* to *v*.

CPM is accurate if fitness differences between genotypes are small, while EPM may provide better estimates if fitness differences are substantial. Indeed, if the fitness effects of all available beneficial mutants exceed some threshold, then fixation probabilities are independent of fitness values \[[@pone.0122283.ref028]\]. We applied both CPM and EPM, since no complete theory for substitution probabilities exists. Additionally, comparison of two models is useful in learning how sensitive our results are for variation in substitution probabilities.

### Time Machine Programs {#sec010}

*Optimal antibiotic sequences and pathways of genotypes*: Let *M*(*f*(*a*)) denote the 16×16 transition matrix we derived for the antibiotic labeled *a* ([S1 File](#pone.0122283.s002){ref-type="supplementary-material"} EPM Prepare and [S2 File](#pone.0122283.s003){ref-type="supplementary-material"} CPM Prepare). For any sequence *a* ~1~,*a* ~2~,...*a* ~*k*~ of *k* antibiotics, we consider the matrix product *M*(*f*(*a* ~1~))*M*(*f*(*a* ~2~))*M*(*f*(*a* ~3~)). This product is also a 16×16 transition matrix. Its entry in row *u* and column *v* is the fixation probability of genotype *u* mutating to genotype *v* under the antibiotic sequence *a* ~1~,*a* ~2~,...,*a* ~*k*~. That probability is a sum of products of entries in the individual matrices *M*(*f*(*a* ~*i*~)), with one sum for each possible pathway of genotypes from *u* to *v*. The Time Machine enumerates all 15^*k*^ antibiotic sequences of length *k*, and it selects all sequences that maximize the entry in row *u* and column *v* of the matrix product ([S3 File](#pone.0122283.s004){ref-type="supplementary-material"} EPM Run and [S4 File](#pone.0122283.s005){ref-type="supplementary-material"} CPM Run). In a subsequent step we then analyze these optimal antibiotic sequences, and for each such sequence, we extract the full list of genotype pathways that contribute ([S5 File](#pone.0122283.s006){ref-type="supplementary-material"} EPM Out and [S6 File](#pone.0122283.s007){ref-type="supplementary-material"} CPM Out).

We implemented this algorithm in the computer algebra software Maple, and we ran it for *k* = 2,3,4,5,6. The running time of the program is slow because of the exponential growth in the number of sequences. At present we do not know whether an efficient algorithm exists for solving our optimization problem for larger values of *k*.

*Cycles of antibiotics*: We also used this method to compute cyclical treatment paths in which the starting and ending genotypes were the wild type 0000 ([S7 File](#pone.0122283.s008){ref-type="supplementary-material"} EPM CyclingOut and [S8 File](#pone.0122283.s009){ref-type="supplementary-material"} CPM CyclingOut). The problem we solved was somewhat different from the previous one, in that we focused on obtaining the maximal probabilities of a cycle that includes some substitutions and then returns to the wild type without halting. Halting means that adjacent genotypes in a mutational pathway coincide, which is undesirable.

Supporting Information {#sec011}
======================

###### Locus Model.

For any biallelic system and set of drugs, the maximum probabilities for returning to the wild-type depend on how many steps one allows in the treatment plan. The following example demonstrates that the maximum probabilities may increase by the number of steps indefinitely. Consider a three-loci system where the genotypes are ordered as 000; 100; 010; 001; 110; 101; 011; 111: Assume that the starting point is the genotype 100 and that Drugs A and B (see the next page) are available. For the sequence A, the probability for ending at 000 is 0.9, for A-B-A 0.99, for A-B-A-B-A 0.999, and so forth.
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###### EPM Out.

Number of paths under the EPM model with the greatest probabilities and the antibiotics and genotypes included in those paths.
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###### CPM Out.

Number of circular paths under the CPM model with the greatest probabilities and the antibiotics and genotypes included in those paths.
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###### EPM Cycling Out.

Number of circular paths under the EPM model with the greatest probabilities and the antibiotics and genotypes included in those paths.
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###### CPM Cycling Out.

Number of circular paths under the CPM model with the greatest probabilities and the antibiotics and genotypes included in those paths.
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